Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc., doing business as Daiichi Pharmaceutical Corp, is a for-profit pharmaceutical manufacturer based in Basking Ridge, New Jersey, that supplies specialty pharmaceuticals to the federal healthcare system exclusively as a prime contractor on unrestricted, full-and-open federal supply schedules and blanket purchase agreements with no socioeconomic set-asides. The company operates 100% as a prime with zero subcontract footprint, competing in the NAICS Pharmaceutical Preparation Manufacturing category (PSC Drugs and Biologicals and Pharmacy Services).

Daiichi Sankyo's federal portfolio is narrowly focused on a single product: TURALIO (pexidartinib), a specialty pharmaceutical indicated for treatment of tenosynovial giant cell tumor. Concrete recent work includes a $208.5 thousand delivery order from the Department of Veterans Affairs Veterans Integrated Service Network 20 in October 2025 for bulk TURALIO supply; recurring monthly delivery orders valued at approximately $22 thousand each from the Department of Justice Federal Medical Center Carswell between February and July 2026; and a $73.7 thousand delivery order from VISN 20 in July 2024, all placed under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB).

The company's customer concentration is dominated by the Department of Veterans Affairs. VISN 12 anchors the potential-value rankings with 3 awards carrying $861.9 million in combined potential value, though obligated dollars across all awards total only $518 thousand. The Veterans Affairs National Acquisition Center contributes 2 awards valued at $1.5 million. The Department of Justice Federal Medical Center Carswell has placed 11 awards (248 thousand combined potential value), while VISN 20 and VISN 22 round out the active set with 6 and 3 awards respectively. Across the five-customer footprint, the potential-value ranking is dominated by VISN 12's large ceiling, while the award-count ranking reflects distributed ordering from Carswell, VISN 20, and VISN 22.

Daiichi Sankyo holds two parent vehicles: a GSA Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) awarded September 1, 2026, with a $250 million ceiling through August 31, 2031; and a single-award Blanket Purchase Agreement with the VA National Acquisition Center valued at $80.2 thousand, effective May 22, 2025, through May 21, 2027, with four optional one-year renewal periods, authorizing VISN 20 and VISN 22 to place delivery orders for TURALIO in 125 milligram and 200 milligram capsule formulations on an as-needed basis. The GSA Schedule generates the majority of activity: 22 task orders with $2 million combined potential value.

Activity has accelerated in 2025 and 2026 after dormancy—one award in 2024, six in 2025, nine in 2026 through September. The company's federal footprint reflects new VA BPA establishment in May 2025 and GSA Schedule placement in September 2026, both supporting a sustained supplier relationship for a rare-disease pharmaceutical to the veteran and federal correctional populations.